RIBS IV: Drug-eluting balloon versus everolimus-eluting stent on in-stent restenosis

This prospective, multicenter, randomized trial compared the paclitaxel-eluting balloon versus everolimus-eluting stent to treat patients with in-stent restenosis. 309 patients were included in total (154 received the drug-eluting balloon, and 155 received the everolimus-eluting stent). There were no differences in the characteristics of both groups. At one year the rate of cardiac death, myocardial infarction and target vessel revascularization was 10% for the everolimus-eluting stent and 18% for the drug-eluting balloon (p = 0.008). The need for revascularization of the target vessel was 4 versus 13%, respectively (p = 0.008). 

Conclusion 

The everolimus-eluting stent showed better angiographic and clinical outcomes than the drug-eluting balloon to treat patients with in-stent restenosis. 

4_fernandoalfonso
Fernando Alfonso
2014-09-15

Original title: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons Versus Everolimus-Eluting Stents in Patients with Coronary In-Stent Restenosis of Drug-Eluting Stents.

More articles by this author

DKCRUSH-VI: FFR versus conventional angiography in true bifurcations and provisional stent

The aim of this study was to compare angioplasty guided by fractional flow reserve (FFR) versus conventional angiography in bifurcations treated with provisional stent...

CTO-IVUS: IVUS clinical impact in total occlusions with 2nd generation DES

While the use of intravascular ultrasound (IVUS) during coronary intervention proved useful in multiple studies, there is limited evidence in the literature regarding its...

OCT-STEMI: Primary angioplasty guided by OCT

This study included 201 patients suffering ST-segment elevation acute coronary syndrome and randomized to the use of optical coherence tomography (OCT) versus conventional angiography...

ABSORB 2: Results at one year of bioabsorbable platform versus Xience

This randomized, controlled, multicenter and blind study compared the second generation of bio-absorbable stent platform with the everolimus-eluting Xience. 501 patients were randomized 2:...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...